Skip to main content
Premium Trial:

Request an Annual Quote

Quest Launches Microarray-Based Test for Chromosome Abnormalities

Quest Diagnostics today said that it is now offering a molecular diagnostic test that can detect chromosome abnormalities associated with 85 developmental disorders affecting children.
 
The ClariSure is a microarray-based comparative genomic hybridization test that will be used to diagnose patients with mental retardation and Down syndrome among other disorders. Quest said it expects to provide physicians with test results within five days of receiving specimens at one of its facilities.
 
The test is based on technologies developed by Quest’s Nichols Institute and other licensed methodologies.
 
“While CGH microarrays are often used for research purposes, the considerable expertise and development required to commercialize these technologies has limited their use for diagnostic testing,” Joyce Schwartz, vice president and chief laboratory officer for Quest, said in a statement. She said the ClariSure assay “bridges the gap” between scientific research and clinical diagnostic testing and provides a faster diagnosis of developmental disorders.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.